Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01210222 · BASELINE

Baseline characteristics

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer · Source last updated 2018-02-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      32
    units
    Participants
groups
  1. description
    Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Trebananib: Given IV
    id
    BG000
    title
    Treatment (Trebananib)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      40 - 49 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          6
      title
      50 - 59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      60 - 69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          14
      title
      70 - 79 years
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Age, Customized
    unit Of Measure
    Participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          32
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligible and evaluable patients
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      32
    units
    Participants
groups
  1. description
    Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Trebananib: Given IV
    id
    BG000
    title
    Treatment (Trebananib)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      40 - 49 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          6
      title
      50 - 59 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      60 - 69 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          14
      title
      70 - 79 years
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Age, Customized
    unit Of Measure
    Participants
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          32
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Eligible and evaluable patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice